Merck & Co., Inc.

Merck & Co., Inc.

MRK

$150.92

Updated: 23/09/2026, 04:10:48

Market Cap
$372.73B
Sector
Healthcare
Industry
Drug Manufacturers - General
Country
US
Stock valuation chart
One-year closing share-price history for MRK
Company Profile

Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.

USD
NYSE
CEO: Robert Davis
Employees: 74,000
https://www.merck.com
Asset Summaries
Latest generated summaries for MRK

No summaries found.

Detailed business
The latest official filing is available; structured extraction is pending.
MRK-10-k-fy2025.html5.0 MBtext/htmlENFiled 24/02/2026Period ended 31/12/2025

The original document can be viewed now. Detailed facts and exposure relationships will appear after the separate extraction job completes.

Full company information
Latest profile, trading, valuation, and identifier data stored for MRK.
Share price
$150.92
Market cap
$372.73B
Exchange
NYSE
Currency
USD
CEO
Robert Davis
Employees
74,000
IPO date
13/01/1978
Beta
0.226
Last dividend
$0.00
Day range
$148.04 – $153.57
52-week range
$77.58 – $156.92
1-day performance
0.95%
1-year performance
94.53%
Current drawdown (1Y)
-3.83%
CIK
0000310158
CUSIP
58933Y105
ISIN
US58933Y1055
Created
07/12/2025, 05:19:32
Last update
23/09/2026, 04:10:48

Track Merck & Co., Inc. with an AI analyst

See which prediction-market events move MRK, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News
News linked to MRK from your Railway `news_articles` table.

Is It Worth Investing in Merck (MRK) Based on Wall Street's Bullish Views?

Zacks Investment Research • STOCK • 12/06/2026, 12:31:04

Merck Animal Health to Acquire TARGAN

Business Wire • STOCK • 11/06/2026, 08:45:00

Merck Stock Moves Above 50-Day SMA: Assessing Its Investment Case

Zacks Investment Research • STOCK • 10/06/2026, 11:42:36

Merck & Co., Inc. (MRK) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Seeking Alpha • STOCK • 09/06/2026, 16:22:17

Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study

Business Wire • STOCK • 08/06/2026, 18:30:00

Mizuho Strategist: Healthcare Is Now a Value Sector as Pharma Stocks Underperform Tech

24/7 Wall Street • STOCK • 07/06/2026, 11:30:55

Merck & Co.: Why The Market Is Right To Start Buying Into Post-Keytruda Promise

Seeking Alpha • STOCK • 05/06/2026, 14:25:36

Merck (MRK) Crossed Above the 50-Day Moving Average: What That Means for Investors

Zacks Investment Research • STOCK • 05/06/2026, 12:31:20

Merck & Co., Inc. (MRK) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Seeking Alpha • STOCK • 04/06/2026, 16:52:54

Merck's Calderasib Gets FDA's Breakthrough Therapy Tag for NSCLC

Zacks Investment Research • STOCK • 01/06/2026, 16:00:28

Can MRK's New Drugs & Pipeline Aid Long-Term Growth Post Keytruda LOE?

Zacks Investment Research • STOCK • 29/05/2026, 13:11:11

FDA Grants Breakthrough Therapy Designation for Calderasib (MK-1084), an Investigational KRAS G12C Inhibitor, for Certain Patients with Newly Diagnosed Metastatic KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC)

Business Wire • STOCK • 29/05/2026, 08:45:00